Article
Nutrition & Dietetics
Hui-Ju Tsai, Wei-Chung Tsai, Wei-Chun Hung, Wei-Wen Hung, Chen-Chia Chang, Chia-Yen Dai, Yi-Chun Tsai
Summary: This study investigated the relationship between gut microbiota and subclinical cardiovascular disease (CVD) in patients with type 2 diabetes (T2D). The findings suggest that certain bacterial species associated with T2D, such as Bacteroidetes and Firmicutes, have correlations with cardiac structure and function. Changes in the gut microbiome, including the Firmicutes/Bacteroidetes ratio and levels of Bacteroides, may serve as potential markers for the development of subclinical CVD in T2D patients.
Article
Medicine, General & Internal
Min Zhuo, Elvira D'Andrea, Julie M. Paik, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Seoyoung C. Kim, Elisabetta Patorno
Summary: The use of SGLT-2 inhibitors is associated with a reduced risk of incident atrial fibrillation in older adults with type 2 diabetes.
Article
Biochemistry & Molecular Biology
Le Deng, Yang Yang, Gaosi Xu
Summary: The study showed that EMPA can ameliorate T2DM-related diabetic nephropathy by altering the gut microbiota, especially by reducing LPS-producing bacteria and increasing SCFA-producing bacteria.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
(2022)
Article
Endocrinology & Metabolism
Limin Wang, Chenghong Liang, Xiaojian Song, Xiaoyan Jia, Xiudan Wang, Yun Zhang, Qinyuan Xie, Nan Zheng, Huijuan Yuan
Summary: This study aimed to assess alterations in the gut, oral, and ocular surface microbiota pre- and post-Cana treatment in patients with type 2 diabetes mellitus (T2DM). The results showed that there were significant changes in the gut, oral, and ocular surface microbiota after Cana treatment, which were related to changes in clinical parameters.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Immunology
Zheng Zhou, Bao Sun, Dongsheng Yu, Chunsheng Zhu
Summary: Type 2 diabetes mellitus, a common metabolic disease, is associated with gut microbiota dysbiosis. Remodeling the gut microbiota may be a potential strategy for treating T2DM and its complications.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Medicine, Research & Experimental
Arpita Arora, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Saurabh Bhatia, Eduardo Sobarzo-Sanchez, Simona Bungau
Summary: Type 2 diabetes mellitus is a prevalent metabolic disorder characterized by high blood sugar, high blood lipids, and insulin resistance, with genetic mutations, obesity, lack of physical activity, and imbalances in gut microbiota being possible contributing factors. The balance of gut microbiota is crucial for maintaining human health.
Article
Endocrinology & Metabolism
Ge Yang, Jinlong Wei, Pinyi Liu, Qihe Zhang, Yuan Tian, Guowen Hou, Lingbin Meng, Ying Xin, Xin Jiang
Summary: Type 2 diabetes is the fastest-growing metabolic disease in the world, with patients often experiencing disturbances in the gut microbiota and increased intestinal permeability. The gut microbiota, which plays a crucial role in metabolism and immune regulation, may serve as a potential therapeutic target for improving the outcomes of type 2 diabetes and related diseases.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Review
Medicine, Research & Experimental
Leilei Du, Qi Li, Huan Yi, Tingting Kuang, Yi Tang, Gang Fan
Summary: This review provides a timely and comprehensive summary of the microbial metabolites that are protective or causative for type 2 diabetes mellitus (T2DM), including amino acids-derived metabolites, short-chain fatty acids, trimethylamine N-oxide, and bile acids. The mechanisms by which these metabolites affect T2DM are elaborated, and frontier therapies targeting gut microbes and their metabolites to improve T2DM are critically discussed, including dietary intervention, fecal microbiota transplantation, probiotics, prebiotics or synbiotics intervention, and drugging microbial metabolism. This review offers novel insights for the development of targeted and personalized treatments for T2DM based on gut microbial metabolites, with the need for more high-quality clinical trials.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Food Science & Technology
Haoran Jiang, Miaomiao Cai, Boyuan Shen, Qiong Wang, Tongcun Zhang, Xiang Zhou
Summary: The number of people with type 2 diabetes mellitus (T2DM) has increased sharply, largely due to factors such as genetic predisposition and unhealthy diet and lifestyle. The consumption of probiotics and prebiotics to gain health benefits has gained acceptance in recent years, with accumulating studies confirming their critical roles in alleviating T2DM symptoms. Synbiotics, a combination of prebiotics and probiotics, show a synergistic effect on T2DM by modulating the gastrointestinal microenvironment.
Article
Nutrition & Dietetics
Yuriko Kondo, Yoshitaka Hashimoto, Masahide Hamaguchi, Ayumi Kaji, Ryosuke Sakai, Ryo Inoue, Saori Kashiwagi, Katsura Mizushima, Kazuhiko Uchiyama, Tomohisa Takagi, Yuji Naito, Michiaki Fukui
Summary: This study examines the association between smoking and gut microbiota, taking into account the impact of smoking on dietary intake. The results show that smoking is associated with both dietary intake and the composition of the gut microbiota.
Review
Endocrinology & Metabolism
Jiaqiang Wu, Kangping Yang, Hancheng Fan, Meilin Wei, Qin Xiong
Summary: This review summarizes the molecular links between gut microbiota-derived metabolites and the pathogenesis of type 2 diabetes mellitus (T2DM). It also reviews potential therapies for T2DM involving modulating the gut microbiota and its metabolites through probiotics, prebiotics, fecal microbiota transplantation, and other methods. Clinical trials investigating the role of gut microbiota and its metabolites are critically discussed. The review highlights the potential therapeutic strategy of targeting the gut microbiota and its metabolites for the prevention and treatment of T2DM.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Gastroenterology & Hepatology
A. L. Cunningham, J. W. Stephens, D. A. Harris
Summary: The evidence supports the impact of gut microbiota on human metabolism, especially in relation to altered glucose homeostasis and the development of type 2 diabetes mellitus (T2DM) and associated complications. Understanding the causal association between gut microbiota and metabolic risk could help identify susceptible individuals for early targeted intervention.
Article
Nutrition & Dietetics
Karolina Drozdz, Katarzyna Nabrdalik, Weronika Hajzler, Hanna Kwiendacz, Janusz Gumprecht, Gregory Y. H. Lip
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common condition associated with type 2 diabetes (T2DM) and cardiovascular disease (CVD). The new term metabolic-associated fatty liver disease (MAFLD) highlights the bidirectional relationships between NAFLD, T2DM, and CVD. Lifestyle changes and targeting the gut microbiota may be important for NAFLD treatment.
Review
Medicine, Research & Experimental
Duygu Agagunduz, Mehmet Arif Icer, Ozge Yesildemir, Tevfik Kocak, Emine Kocyigit, Raffaele Capasso
Summary: Type 2 diabetes mellitus (T2DM) is a systemic inflammatory disease characterized by dysfunctional pancreatic beta-cells and insulin resistance, and it is influenced by genetic, metabolic, lifestyle, and sociodemographic factors. The disease is also affected by dietary lipids, lipid metabolism, and gut microbiota. Lipidomics analysis has shown potential in understanding the pathogenesis and progression of T2DM. Understanding the interactions between dietary lipids, lipidomics, and gut microbiota can lead to new strategies for the prevention and treatment of T2DM.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Andrea Piccioni, Federico Rosa, Sergio Mannucci, Federica Manca, Giuseppe Merra, Sabrina Chiloiro, Marcello Candelli, Marcello Covino, Antonio Gasbarrini, Francesco Franceschi
Summary: This article focuses on the relationship between alterations in the gut microbiome and the onset of type 1 diabetes mellitus and LADA, based on the latest evidence. It discusses the crucial role of the gut microbiota in the pathogenesis of these disorders and explores how modulating the gut microbiota through probiotics, prebiotics, and fecal microbiota transplantation can lead to potential therapeutic strategies.
Article
Endocrinology & Metabolism
Limin Wang, Tingting Chen, Jiawei Yu, Huijuan Yuan, Xinru Deng, Zhigang Zhao
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
(2020)
Review
Biochemistry & Molecular Biology
Xinru Deng, Pengxu Wang, Huijuan Yuan
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
(2020)
Article
Endocrinology & Metabolism
Yuanyuan Fang, Chenhong Zhang, Hongcai Shi, Wei Wei, Jing Shang, Ruizhi Zheng, Lu Yu, Pingping Wang, Junpeng Yang, Xinru Deng, Yun Zhang, Shasha Tang, Xiaoyang Shi, Yalei Liu, Huihui Yang, Qian Yuan, Rui Zhai, Huijuan Yuan
Summary: The gut microbiota and metabolites in patients with LADA show distinct characteristics compared to healthy individuals and patients with type 1 and type 2 diabetes, with a severe deficiency of short-chain fatty acid-producing bacteria. The gut microbiota structure of patients with LADA is more similar to patients with type 1 diabetes who are positive for GAD antibody.